Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 28.42M
March 31, 2026 28.42M
December 31, 2025 28.41M
September 30, 2025 27.24M
June 30, 2025 27.15M
March 31, 2025 27.12M
December 31, 2024 27.00M
September 30, 2024 27.08M
June 30, 2024 27.04M
March 31, 2024 26.92M
December 31, 2023 26.83M
September 30, 2023 26.72M
June 30, 2023 26.57M
March 31, 2023 26.56M
December 31, 2022 26.56M
September 30, 2022 26.49M
June 30, 2022 26.43M
March 31, 2022 26.41M
December 31, 2021 26.37M
September 30, 2021 26.35M
June 30, 2021 26.33M
March 31, 2021 26.32M
December 31, 2020 26.19M
September 30, 2020 15.14M
June 30, 2020 20.30M
Date Value
March 31, 2020 14.53M
December 31, 2019 15.14M
September 30, 2019 15.13M
June 30, 2019 13.12M
March 31, 2019 10.72M
December 31, 2018 10.72M
September 30, 2018 10.74M
June 30, 2018 10.74M
March 31, 2018 10.69M
December 31, 2017 10.66M
September 30, 2017 3.938M
June 30, 2017 3.938M
March 31, 2017 3.938M
December 31, 2016 3.938M
September 30, 2016 3.937M
June 30, 2016 3.937M
March 31, 2016 3.937M
December 31, 2015 3.937M
September 30, 2015 2.886M
June 30, 2015 2.886M
March 31, 2015 2.886M
December 31, 2014 1.958M
September 30, 2014 1.948M
June 30, 2014 1.948M
March 31, 2014 1.948M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 172.13M
Emergent BioSolutions, Inc. 51.30M
Exelixis, Inc. 248.88M
Ionis Pharmaceuticals, Inc. 165.64M
United Therapeutics Corp. 42.68M